CAR T newco Autolus debuts with L30M series A

Immunotherapy company Autolus Ltd. (London, U.K.) closed a L30 million ($45.5 million) series A round from Syncona Partners. The University College London spinout is developing chimeric antigen receptor (CAR) T cell therapies to treat hematological and solid tumors, including some it says cannot be addressed with other CAR T therapies. ...